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A new measles mumps rubella (MMR) vaccine: a randomized 
comparative trial for assessing the reactogenicity and 
immunogenicity of three consecutive production lots and 
comparison with a widely used MMR vaccine in measles 
primed children 
Chin-Yun Lee,(l) Ren-Bin Tang,t2) Fu-Yuan Huang,c3) Haiwen Tang,t4) Li-Min Huang(l) 
and Hans L. Bockc4) 
Objectives: A multicenter, single-blind, randomized, controlled clinical study was conducted in healthy 1%18-month- 
old children in order to assess the immunogenicity and reactogenicity of three consecutive lots of a new measles- 
mumps-rubella (MMR) vaccine, GSK MMR. 
Design: A total of 500 enrolled subjects were randomized into four groups to receive either a single dose of one of 
the three lots of GSK MMR (three groups - 125 subjects in each group) or Merck MMR vaccine (125 subjects). 
Once clinical consistency had been demonstrated, the data were pooled and compared with the widely used Merck 
vaccine. Solicited local and general symptoms were recorded using diary cards, and antibody levels were determined 
using ELISA assays. 
Results: No differences in the incidence of local and general symptoms or seroconversion rates were seen in the 
groups receiving different lots of GSK MMR. Compared with Merck MMR, there was a significantly lower incidence 
of local pain (P<O.OOl) and swelling (P=O.O38) in infants receiving the GSK MMR vaccine. The incidences of all 
other solicited local and general symptoms were comparable between the two groups. No signs of suspected 
meningitis were reported. No serious adverse events were reported by the investigator to be related to vaccination. 
Equivalent seroconversion rates and postvaccination GMTs were observed in the groups receiving the two MMR 
vaccines. In conclusion, the new GSK MMR vaccine administered in measles-primed children demonstrated 
satisfactory immunogenicity and safety profiles as good as the Merck MMR vaccine. 
Int J Infect Dis 2002; 6: 202-207 
Each year measles, mumps, and rubella affect millions of 
children around the world and many of them will die or 
suffer long-term illness from complications arising from 
these vaccine-preventable diseases. In view of the high 
incidence of measles-associated infant mortality, measles 
vaccination was introduced into the Expanded Program 
of Immunization in 1978.(r) The first step towards the 
eradication of measles is to implement a primary vaccin- 
ation program. However, early vaccination programs 
showed that a single dose did not provide sufficiently 
high coverage levels to interrupt the transmission of the 
wild-type virus. 2-5 Therefore a second dose is recom- 
mend to catch unvaccinated individuals and primary 
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vaccine failures.3-5 In regions with a high risk of measles 
infection, such as Taiwan, a monovalent dose of measles 
is recommended at nine months of age. However, at this 
age there is a high likelihood of primary vaccine failure 
because of potential interference from maternal anti- 
bodies coupled to the young age of the vaccines2 There- 
fore a second dose of measles vaccine at 1.5 months of 
age is recommended with the use of the MMR vaccine 
(thereby also giving the first doses of rubella and mumps). 
In Europe and the US, where the risk of measles 
infection is lower, a two-dose MMR strategy has been 
widely adopted and is in fact now recommended in 
many of these countries. The first dose is given in the 
second year of life, and the second at either 4-6 years or 
11-12 years as catch-up to cover primary vaccine 
failures and individuals who missed the first dose. Such 
two-dose strategies have led to an increased coverage 
and the successful maintenance of herd immunity, sub- 
sequently resulting in reducing the incidence of these 
diseases. 6~7 
Until 1992, in most parts of the world the most 
widely used MMR vaccines were M-M-R II (Merck & 
Co Inc.), produced by Merck & Co. Inc., and Pluserix, 
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produced by GlaxoSmithKline Biologicals. M-M-R II 
vaccine contains the Enders Edmonston measles strain, 
the Jeryl Lynn mumps strain, and the RA/27/3 rubella 
strain, and is used extensively in the US, Europe, and 
other parts of the word. Pluserix contains the Schwarz 
measles strain, the Urabe Am 9 mumps strain, and the 
RA27/3 rubella strain. Both have been shown to be 
highly effective. However, an increased risk of aseptic 
meningitis after immunization of the Urabe strain has 
been rep0rted.s Although the benefits of vaccination 
with Urabe strain-derived vaccines far outweigh the 
relatively low risk of benign cases of aseptic meningitis, 
vaccines containing this strain have been withdrawn 
from markets in certain countries. 9, lo 
Recently GlaxoSmithKline has developed a new 
MMR vaccine, GSK MMR, containing a mumps strain 
RIT 4385, which is Jeryl Lynn-strain derived. The objec- 
tive of this study was to evaluate the reactogenicity and 
immunogenicity of the new MMR vaccine with a com- 
mercially available and widely used Merck vaccine, M-M- 
R II (Merck MMR), when administered to children aged 
between 12 and 18 months in a population routinely 
receiving monovalent measles at nine months of age. 
MATERIALS AND METHODS 
Study design and participants 
The study was conducted at the following study centers 
in Taiwan: National Taiwan University Hospital, 
Veterans General Hospital, and Mackay Memorial 
Hospital. The study received approval from each of the 
Institutional Review Boards of these hospitals and the 
Department of Health. The study was conducted 
according to the Declaration of Helsinki and Good 
Clinical Practice Guidelines. Written informed consent 
was obtained from the parents or the guardians of all 
subjects prior to enrolment in the study. 
Subjects and procedures 
A total of 500 healthy infants aged between 12 and 
18 months were enrolled in the study. Subjects were 
randomized into four groups; the first three groups 
received a single dose from consecutive production lots 
of GSK MMR (Priorix*, GlaxoSmithKline Biologicals), 
and the fourth group received a single dose of Merck 
MMR (M-M-R IIt, Merck & Co Inc.). Data from all 
subjects were collected for the reactogenicity analysis. A 
sub-population of 225 subjects were evaluated in the 
immunogenicity analysis. 
Children were excluded from the trial if they had 
been knowingly exposed to mumps or rubella 30 days 
prior to the trial or previous history of these infections. 
*‘Priorix’ is a trade mark of the GlaxoSmithKline group of companies. 
‘M-M-R II is a trade mark of Merck & Co Inc. 
Other exclusion criteria included allergy to neomycin 
and/or egg proteins, upper respiratory tract infection, 
tuberculosis, history of convulsions (including febrile), 
epilepsy or any other CNS disorder, administration of 
parenteral vaccines within 30 days of the start of the 
trial, immune disorders (including HIV infection), 
immunosuppressive and immunoglobulin therapy, or 
administration of blood products within 30 days of the 
start of the trial. 
Vaccines 
Each vaccine lot used met the WHO requirements 
for MMR vaccines, i.e., minimum virus titres of 2103,() 
CCID50, r103.’ CCIDso and r103.0 CCID5o for the 
measles, mumps, and rubella components, respectively. 
The mumps strain RIT 4385 was developed by Glaxo- 
SmithKline Biologicals and was derived by limit dilution 
of a commercial lot of a monovalent mumps vaccine. 
It has been shown to be a pure clone of the dominant 
of two virus populations found in the Jeryl Lynn strain 
source vaccine.‘“,” Each vaccine was prepared by recon- 
stituting the freeze-dried pellet in 0.5 ml ampoule of 
water. The vaccine was administered by the investigator 
via a subcutaneous injection into the upper left arm. 
Reactogenicity assessment 
Diary cards were used by parents (who were also 
blinded as to which vaccine their child had received) to 
record solicited local adverse experiences (pain on 
digital pressure, redness, and swelling) on the day of 
vaccination and on three subsequent days. General 
adverse experiences (fever, rash, parotid gland swelling 
and signs of suspected meningitis) were monitored on 
the day of vaccination and for 41 subsequent days. Any 
redness or swelling was measured, a diameter >20 mm 
being defined as severe. Fever was assessed qualitatively 
with a temperature sensitive pad. A rectal temperature 
of >39.5”C was defined as severe. For all other symptoms, 
severe was defined as an adverse experience that 
prevented normal daily activities. In cases of parotid 
swelling, parents were asked to take the child to the 
investigator, and saliva samples were taken. Severe 
parotid swelling was defined as swelling with additional 
general symptoms. If any febrile convulsions or any 
other neurological signs or symptoms indicative of 
meningism (e.g., vomiting, neck stiffness, photophobia) 
were reported, they were followed up by neurological 
examination according to local medical practice (lumbar 
puncture was at the investigator’s discretion). Polymer- 
ase chain reaction (PCR) was to be used to detect the 
mumps virus in saliva samples and cerebrospinal fluid 
(CSF). All other symptoms or reactions occurring within 
40 days postvaccination were recorded as unsolicited, 
The investigator recorded the outcome of all adverse 
experiences and assessed the relationship of unsolicited 
symptoms and general reactions to the vaccination. 
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Figure la: Post vaccination anti-measles GMTs for 3 
consecutive production lots of SB MMR 
Figure 1 b: Post vaccination anti-mumps GMTs 
following 3 consecutive production lots of SB 
Significant difference observed between lots p = 0.013 
Figure Ic: Post vaccination anti-rubella GMTs following 
3 consecutive production lots of SB MMR 
Figure 1. Postvaccination GMTs in subjects receiving three consecutive manufacturing lots of GSK MMR. 
Significant difference observed between lots P=O.O13. 
Immunogenicity assessment mercial ELISA kits (Enzygnost, Behring).The assay cut- 
offs were: 150 mIU/ml for measles; 231 U/ml for mumps; 
Sera samples taken on the day of vaccination and within and 4 IU/ml for rubella. An antibody titer greater or 
40-63 days post vaccination were stored at -20°C equal to the cut-off was defined as seropositive. In 
until analysis was performed in a blinded fashion at initially seronegative subjects, seroconversion was 
GlaxoSmithKline Biologicals Rixensart, Belgium. All defined as the appearance of detectable antibody levels. 
antibody titers were measured with the use of com- Geometric mean titers (GMTs) were calculated. 
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Table 1. Local and general symptoms in subjects receiving three consecutive manufacturing lots of 
GSK MMR 
Symptoms 
MJR 114A43 MJRI ISA43 MJRI 16A43 Overall 
(N=114) (N=719) (N=114) t-Test 
n % n % n % P- Value 
Local symptoms 
pain on digital pressure 
severe 
redness 
>20 mm 
swelling 
>20 mm 
8 7.0 7 5.9 5 4.3 0.682 
0 0.0 0 0.0 0 0.0 - 
7 6.1 6 5.0 7 6.1 0.918 
0 0.0 0 0.0 2 1.7 - 
4 3.5 4 3.4 4 3.5 1.000 
0 0.0 0 0.0 1 0.9 - 
General 
fever r38.1”C 
r39.5”C 
parotid gland swelling 
severe 
rash 
generalized rash with fever 
34 29.8 34 28.6 34 29.6 0.977 
5 4.4 5 4.2 6 5.2 - 
2 1.8 5 4.2 1 0.9 0.699 
0 0.0 1 0.8 0 0.0 - 
8 7.0 9 7.6 10 8.7 0.908 
0 0.0 1 0.8 0 0.0 - 
N=number of symptom sheets returned. 
n=number of symptoms reported (for local reactions); number of subjects with at least one symptom (general 
reactions). 
Severe was defined as ‘preventing normal everyday activities-‘. 
*Statistically significant (n level 0.05) 
Statistical analysis 
The primary objective of this study was to assess in 
healthy children the reactogenicity and immunogenicity 
of three consecutive production lots of GSK measles- 
mumps-rubella (MMR) vaccine and to compare it with 
an established MMR vaccine. All statistics were 
performed with SAS with a type 1 error of 5%. The trial 
was divided into two phases: 
Consistency phase: the Fisher’s exact test was used to 
compare the incidence of the overall reporting of local 
and general symptoms in the three groups receiving 
consecutive manufacturing lots of GSK MMR. The 
Fisher’s exact test was used to compare the serocon- 
version rates and a one-way ANOVA was used to 
compare postvaccination GMTs in groups receiving 
different lots of GSK MMR. 
Comparative phase: if no differences between lots were 
found in the incidence of symptoms and seroconversion 
rates, the data from groups receiving GSK MMR were 
pooled. The pooled data for the GSK MMR groups 
(group 1) was then compared to the group receiving 
Merck MMR (group 2). Fisher’s exact test was used to 
compare incidence of local and general symptoms and 
seroconversion rates a one-way ANOVA to compare 
postvaccination GMTs in the two groups. 95% con- 
fidence intervals (95%CI) were calculated for the 
incidence of all symptoms and seroconversion rates and 
pre- and postvaccination GMTs 
RESULTS 
Five hundred subjects were enrolled and vaccinated: 468 
completed the study to day 60. Out of the 32 subjects 
who dropped out of the study, 26 were lost to follow up. 
A further six subjects came to the second visit, but no 
second blood sample was taken (protocol violation). 
There were no drop-outs or withdrawals because of 
adverse events or serious adverse events. 
Reactogenicity in vaccinees who received one of three 
lots of GSK MMR 
There was no difference between the three lots of 
GSK MMR for any of the solicited symptoms recorded 
(Table 1). 
Immunogenicity in vaccinees who received three lots 
of GSK MMR 
Subjects were divided according to prevaccination 
status. There was no difference between the groups in 
seroconversion rates (Table 2) or postvaccination GMTs 
in initially seronegative subjects: (Figure la and lc), with 
the exception of a lower antimumps GMT (P=O.O13) in 
the group receiving lot MJR 116A43 (Figure lb). The 
routine medical practice of administering a monovalent 
Table 2. Seroconversion rates in initially seronegative subjects 
receiving three consecutive manufacturing lots of GSK MMR 
Vaccine 
MJRl14A43 MJRI ISA43 MJRI 16A43 
n/N* % SC n/N % SC n/N % SC 
Antimeasles 7f7 100.0 8/S 100.0 18/18 100.0 
Antimumps 46151 90.2 53156 94.6 44146 95.7 
Antirubella 52152 100.0 57157 100.0 46/46 100.0 
Fishers t-test for comparison of seroconversion rates: antimumps 
P=O.522; no statistical comparison made for antimeasles because 
number of subjects was too small nor for antirubella since all subjects 
had seroconverted. 
100% true 
*Number of seropositive subjects/number of total vaccinees. 
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Table 3. Pre- and postvaccination GMTs of measles in initially 
seropositive subjects receiving three consecutive manufacturing 
lots of GSK MMR 
Prevaccination GMT Postvaccination GMT 
Vaccine (95% Cl) (95% C/J 
MJRI 14A43 1880.8 3202.4 
(1474-2400) (2648-3873) 
MJRI 15A43 1482.5 3616.8 
(1190-1847) (3 192-4098) 
MJRI 164A3 1633.1 3061 .O 
(1230-2168) (2579-3633) 
Analysis of initially seropositive subjects was not a study objective, 
therefore no inferential statistical analysis was performed. However, the 
descriptive analysis using 95% Cl suggests no difference between groups 
for either pre-vaccination or postvaccination titers. 
dose of measles at nine months of age in Taiwan, 
which could account for the high percentage (calculated 
average for whole cohort) of subjects seropositive for 
antimeasles in this study cohort (Table 3). However, no 
differences in pre- or postvaccination GMTs were seen 
between groups (as shown by 95%CI). 
Comparison of reactogenicity in vaccinees who 
received GSK MMR and Merck MMR 
All 500 subjects were included in the intention-to-treat 
analysis of reactogenicity. The mean age of these 
children was 15.1 months (range lo-22 months). Since 
no differences between the three consecutive produc- 
tion lots of GSK MMR were observed in terms of 
reactogenicity or immunogenicity criteria, data of three 
lots of GSK MMR were pooled and compared with 
Merck MMR. 
As shown in Table 4, there was a significantly lower 
(P=O.OOl) incidence of pain at the injection site (evalu- 
ated by the application of digital pressure) between the 
pooled GSK MMR groups (5.7%) and the Merck MMR 
group (15.8%). The incidence of swelling was signifi- 
cantly higher (P=O.O38) in the Merck MMR group (8.8 
%) compared with the GSK MMR groups (3.4%). The 
overall incidence of fever was similar in two groups with 
29.3% for the GSK MMR group and 28.9% for Merck 
MMR group (P=l.OOO). The onset of the majority of 
fever cases was reported during week one and two of the 
follow-up period, with a peak in the incidence of fever 
between days 5 and 10 postvaccination. There was no 
difference in incidence of high fever (>39.5”C) in all 
groups. No signs of suspected meningism (including 
febrile convulsions) were reported. Six subjects experi- 
enced parotid gland swelling. Four cases were recorded 
in the GSK MMR group (1.1%) and two (1.8%) in the 
Merck MMR group. The incidence of rash was similar in 
both groups, most of them occurring within the first two 
weeks postvaccination. Most cases showed localized 
rash without fever and there was only one report of 
generalised rash with fever (Merck MMR group). 
Comparison of immunogenicity in vaccinees who 
received GSK MMR and Merck MMR 
Sera from 225 children were evaluated and the results 
from 204 children were included in the immunogenicity 
analysis; 21 subjects were excluded from the analysis 
because they did not meet the criteria stipulated in the 
protocol. The mean age of these subjects was 15.4 
months (range 11-22 months). 
Table 4. Incidence of local and general symptoms after vaccination with three lots of 
GSK MMR and one of Merck MMR 
Symptoms 
Local symptoms 
pain on digital pressure 
severe 
redness 
>20 mm 
swelling 
~20 mm 
GSK MMR* Merck MMR 
(N = 348) (N= 114) Fisher’s Test 
n % n % P- values 
20 5.7 18 15.8 <0.001** 
0 0.0 0 0.0 - 
20 5.7 9 7.9 0.383 
2 0.57 0 0.0 - 
16 3.4 IO 8.8 0.038** 
1 0.29 1 0.9 - 
General symptoms 
fever 238.1 
>39.5”C 
parotid gland swelling 
severe 
rash 
rash with fever 
102 29.3 33 28.9 1.000 
16 4.6 5 4.4 - 
4 1.1 2 1.8 0.640 
0 0.0 0 0.0 - 
27 7.7 11 9.6 0.556 
1 0.28 0 0.0 - 
N=number of symptom sheets returned. 
n=number of symptoms reported (for local reactions); number of subjects with at least one 
symptom (general reactions). 
Severe was defined as ‘preventing normal everyday activities’. 
*Pooled data of three lots of GSK MMR. 
**Statistically significant Q level 0.05). 
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In the initially seronegative subjects, both groups 
developed antirubella and antimeasles antibodies (Table 
5). A total of 93.5 and 97.9% of subjects respectively 
seroconverted with respect to antimumps antibodies. No 
difference was seen in postvaccination GMTs in groups 
for any antibody, although the numbers of initially 
antimeasles seronegative subjects were too small to 
allow statistics to be performed. 
DISCUSSION 
The aim of recent vaccine development has been to 
improve the protective capacity and the safety and 
reactogenicity profile of MMR vaccines. Obtaining a 
balance between these two factors has not always been 
easy. In this trial both vaccines were shown to have a 
good reactogenicity profile, although the GSK MMR 
was better tolerated in terms of local reactions. Both 
elicited a comparable immunogenicity when used at 15 
months of age.The large number of initially seropositive 
children with respect to measles is not wholly surprising 
given that it is routine medical practice in Taiwan to 
vaccinate with a monovalent dose of measles at nine 
months of age. It appears that both MMR vaccines 
can be given with an acceptable tolerability after a 
monovalent dose of measles in early life. Indeed it has 
previously been reported that an MMR vaccine can be 
given in such a manner.2.12 Furthermore, the GSK MMR 
vaccine was shown to have a better injection site reacto- 
genicity profile than the Merck MMR vaccine.13,i4 
Lower incidence of pain and swelling at the injection 
site may confer a benefit in terms of parent preference. 
Experience with aseptic meningoencephalitis 
following vaccination with the Urabe strains of mumps 
vaccine underscores the importance of monitoring 
vaccine safety of any new mumps vaccines.8,9 Based in 
part on this experience, the new RIT 4385 strain was 
developed and consequently every effort was made to 
detect any case of aseptic meningitis. However, given the 
low risk of aseptic meningitis, coupled to the relatively 
small sample size, a number of accepted surrogate 
markers9J8 for aseptic meningitis were also used in an 
effort to detect possible cases. Therefore in common 
with other studies9Js, the incidence of febrile convulsions 
and fever (peak incidence in the 15-35 day risk period 
post vaccination) was used as a surrogate marker 
for meningitis. No cases of febrile convulsions were 
reported in this trial. The majority of the cases of fever 
were confined to the first two weeks post vaccination, 
which is known to be associated with the measles com- 
ponent of the MMR vaccine.15-18 However, there was no 
fever peak within the 15-35 days postvaccination period, 
which is considered to be a marker for suspected aseptic 
meningitis. This result has also been confirmed in 
controlled clinical trials involving more than 4500 
children.i3J9 Furthermore, as mentioned earlier, the 
risk of aseptic meningitis is low, and large numbers of 
vaccinees will be needed before the risk can be 
unequivocally ruled out. 
The consistency of manufacturing of GSK MMR 
vaccine was also examined in this study. In terms of 
seroconversion rate for measles, mumps, and rubella, no 
difference was found between the three consecutive lots 
of GSK MMR. GMTs for measles and rubella were also 
similar between the three lots of GSK MMR. Although 
a statistical difference was observed for the GMTs of 
antimumps antibodies at day 60 post immunization in 
GSK MMR vaccine, this is unlikely to be of any clinical 
significance. Similar differences have been observed in 
the antibody levels; from subject to subject, in different 
lots of the same strain and in different strains, even 
when similar assays are used to measure the antibody 
levels.12J5.20 Furthermore at month 12 post immuniz- 
ation, similar GMTs for measles, rubella, and mumps 
antibodies were observed in both GSK groups and the 
Merck group (data not shown). These data from the 
consecutive lots of GSK MMR vaccines demonstrated 
an excellent clinical consistency of manufacturing 
Table 5. Comparison of seroconversion rates and postvaccination GMTs in initially seronegative 
subjects 
GSK MMR* Merck MMR 
Antibody nlN % SC GMT (95% Cl) nlN % SC GMT (95% Cl) 
Antimeasles 33133 100.0 2342.5 16116 100.0 2548.8 
(1761-3115) 
Antimumps 
(1643.3-3953.3) 
1431153 93.5 887.8 46147 97.9 1097.4 
(794.8-991.8) 
Antirubella 
(878.1-1371.5) 
1551155 100.0 128.8 47147 100.0 140.3 
(199.8-138.5) (122.2-161.1) 
N=number of subjects analyzed. 
n=number of seropositive subjects postvaccination. 
% SC=percentage of seroconverted subjects. 
GMT values are expressed in mlU/ml for antimeasles; U/ml for antimumps; lU/ml for antirubella antibodies. 
*Pooled data of three lots of GSK MMR. 
Comparison of seroconversion rates in groups for antimumps (P=O.464). No statistical analysis performed on: 
antimeasles seroconversion rates because numbers were too small, and all antirubella subjects were seroconverted. 
Comparison of postvaccination GMTs in groups for antirubella (P=O.264). No statistical analysis performed on 
antimeasles GMTs because numbers were too small; and antimumps GMTs were shown not be consistent between 
the three lots of Priorix. 
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processes, which has also been confirmed in several 
other studies.13,i9 
Extensive data have demonstrated that serocon- 
version provides immunity to later exposure to the 
measles, mumps, and rubella virus.7,12,20-26 In this study, 
equivalent seroconversion rates for all three com- 
ponents were found in the GSK MMR and Merck 
MMR vaccine (Table 5). These data are also in line with 
the results obtained in Usonis’s study with large 
numbers of subjects.r3,r9 
In Taiwan, a two-dose measles vaccination was 
introduced in 1988, one dose at nine months and one 
dose at 15 months of age. Since 1992, the second dose of 
measles vaccine has been changed to the MMR 
vaccine.2T27 A recent survey in 1994 showed that the 
measles antibody seropositivity rate reached 85.5% at 
the age of 12-24 months, and the seropositivity rate rose 
further to 89.2% after two years of age.27 This vaccine 
program greatly reduced the incidence of measles since 
the last epidemic in 1989 in Taiwan. In this study, both 
GSK and Merck MMR vaccines administrated as the 
second dose at 15 months induced 100% seroconversion 
for measles and rubella, and over 90% seroconversion 
for mumps. The GMTs of the three viral antibodies six 
weeks after injection were high and well above the 
protective levels, demonstrating the excellent immuno- 
genicity of these vaccines. 
High coverage of measles vaccination is one of 
the key requirements in the global effort to eliminate 
measles. The two-dose strategy is necessary to achieve 
high vaccine coverage, and this is needed to maintain 
herd immunity.4q28 As mentioned earlier, the success of 
the two-dose MMR vaccination strategy in Europe and 
US is exemplified by the situation in Finland, where an 
immunisation program using two doses of combined live 
virus vaccine has led to the virtual elimination of this 
disease.7 The newly developed GSK MMR vaccine, with 
a similar immunogenicity profile to the Merck MMR 
vaccine, but with improved local tolerability, provides an 
attractive alternative for health care professionals in the 
regions where a monovalent dose of measles is routinely 
given at nine months of age. 
REFERENCES 
1. World Health Organisation (WHO): Expanded Programme 
on Immunisation - accelerated measles strategies Wkly. 
Epidemiol Ret 1994; 69:229-34 
2. Huang L-M, Lee C-Y, Hsu C-Y, et al. Effect of monovalent 
and trivalent measles-mumps-rubella vaccines at various 
ages and concurrent administration with hepatitis B 
vaccine. Pediatr Infect Dis. J 1991; 9:461-5. 
3. De Quadros C, Olive J-M, Hersh BS, et al. Measles 
elimination in the Americas. JAMA 1996; 275224-9. 
4. Anonymous. Measles eradication: Recommendations from 
a meeting cosponsored by the World Health Organization, 
the Pan American Health Organization and CDC. Morbid 
Mortal Wkly Rep 1997; 46(rr-ll):l-2 
5. Bock LH, Usonis V, Mohs AA, et al. Review of recent 
6. 
developments in MMR vaccination and practices in Latin 
America. Rev Med Cir 1999; 1:39-49. 
Hilleman MR. The development of live attenuated mumps 
virus vaccine in historic perspective and its role in the 
evolution of combined measles-mumps-rubella. In: Plotkin 
SA, Fantini B,eds. Vaccinia, vaccination and vaccinology: 
Jenner, Pasteur and their successors. Paris: Elsevier, 1996; 
pp. 283-92. 
Peltola H, Heinonen OP, Valle M, et al. The elimination of 
indigenous measles, mumps and rubella from Finland by a 
12 year, two-dose vaccination program. N Engl J Med 
1994; 331:1397-402. 
8. 
9. 
10. 
Balraj V, Miller E. Complications of mumps vaccines. Rev 
Med Viroll995; 5: 219-27. 
Miller E, Goldacre M, Pugh S, et al. Risk of aseptic 
meningitis after measles, mumps and rubella vaccine in 
UK children. Lancet 1993; 341:979-82. 
Takeuchi K, Tanabyashi K, Hishiyama M, Yamada A, 
Sugiura A. Variations of nucleotide sequences and tran- 
scription of the SH gene among mumps virus strains. 
Virology 1991; 181:364-6. 
11. Afzal MA, Pickford AR, Forsey T, Heath AB, Minor 
PD. The Jeryl Lynn vaccine strain of mumps virus is a 
mixture of two distinct isolates J Gen Virol 1993; 
74:917-20 
12. 
13. 
14. 
15. 
16. 
Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, 
Mortimer EA, eds. Vaccines. Philadelphia: Saunders, 1994; 
pp. 229-60. 
Usonis V, Bakasenas V, Citour K, Clemens R. Comparative 
study of reactogenicity and immunogenicity of a new 
measles, mumps and rubella vaccine Priorix and M-M-R II 
in healthy children. Infection 1998; 26:222-6. 
Gatchalian S, Cordero-Yap L, Lu-Fong M et al. A 
randomized comparative trial in order to assess the 
reactogenicity and immunogenicity of a new measles 
mumps rubella (MMR) vaccine when given as a first dose 
at 12-24 months af age. Southeast Asian J Trop Med Hyg 
1999; 30:511-17. 
Stocks J, Weibel RE,Villarejos VM, Arguedas JA, Buynak 
EM, Hilleman MR. Trivalent combined measles-mumps- 
rubella vaccine. JAMA 1971; 218:57-61. 
Farrington P, Pugh S, Colville A et al. A new method for 
active surveillance of adverse events from diphtheria/ 
tetanus/pertussis and measles/mumps/rubella vaccines. 
Lancet 1995; 345:567-9. 
Christenson B, Bottiger M. Methods for screening the 
naturally acquired and vaccine-induced immunity to the 
mumps virus. Biologicals 1990; l&213-19. 
Kimura M, Kuno-Sakai H, Yamazaki S et al. Adverse 
events associated with MMR vaccines in Japan. Acta 
Paediatrica Japonica 1996; 38: 05-l 1. 
Usonis V, Bakasenas V, Bock H, Chitour K, Clemens R. 
Reactogenicity and immunogenicity of a novel live 
attenuated combined measles, mumps and rubella vaccine 
in healthy children. Ped Inf Dis J 1999; l&42-8. 
Plotkin S. Rubella vaccine. In: Plotkin SA, Mortimer EA, 
eds. Vaccines. Philadelphia: Saunders, 1994; pp. 303-26. 
17. 
18. 
19. 
20. 
31 aI. Cochi SL, Wharton M, Plotkin SA. Mumps vaccine. In: 
Plotkin SA, Mortimer EA, es. Vaccines. Philadelphia: 
Saunders, 1994; pp. 277-301. 
22. Chen RT, Markowitz LE, Albrecht P, et al. Measles 
antibody: reevaluation of protective titers. J Infect Dis. 
1990; 162:103642 
23. Samb B, Aaby P, Whittle HL, et al. Serologic status and 
measles attack rates among vaccinated and unvaccinated 
children in rural Senegal. Pediatr Infect Dis J 1995; 14: 
203-9. 
24. Skendzel LP. Rubella immunity: defining the level of 
protective antibody. Am J Clin Path01 1996; 106:170-4. 
25. Hilleman MR, Stokes J, Buynak EB, Weibel R, Halenda R, 
Goldner H. Enders’ live measles-virus vaccine with human 
immune globulin. Am J Dis Child 1962; 103:372-9. 
A new measles mumps rubella (MMR) vaccine I Lee et al 209 
26. Hilleman MR, Weibel RE, Buynak EB, Stokes J, Whitman 
JE. Live attenuated mumps-virus vaccine. New Engl J Med 
1967; 276:252-g. 
27. Chiu H-H, Lee C-Y, Chih T-W, et al Seroepidemiological 
study of measles after the 1992 nationwide MMR re- 
vaccination program in Taiwan. J Med Viol 1997; 51:32-5. 
28. Anderson RM, May RM. Immunisation and herd immunity: 
A Lancet review. 1n:Arnold E ed. Modem vaccines. Current 
practice and new approaches. Lancet 1990; 335:24-33. 
